Safety, pharmacokinetic, and efficacy studies of oral DB868 in a first stage vervet monkey model of human African trypanosomiasis.

• Main Authors: John K Thuita (Author), Kristina K Wolf (Author), Grace A Murilla (Author), Qiang Liu (Author), James N Mutuku (Author), Yao Chen (Author), Arlene S Bridges (Author), Raymond E Mdachi (Author), Mohamed A Ismail (Author), Shelley Ching (Author), David W Boykin (Author), James Edwin Hall (Author), Richard R Tidwell (Author), Mary F Paine (Author), Reto Brun (Author), Michael Zhuo Wang (Author)
• Format: Book
• Published: Public Library of Science (PLoS), 2013-01-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

There are no oral drugs for human African trypanosomiasis (HAT, sleeping sickness). A successful oral drug would have the potential to reduce or eliminate the need for patient hospitalization, thus reducing healthcare costs of HAT. The development of oral medications is a key objective of the Consor...